Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities. As a commercial‑stage orthopaedic device company with a portfolio centered on 3D bunion correction, Treace regularly issues news on product innovation, clinical evidence, financial performance and capital structure.
On this page, readers can follow TMCI news covering quarterly and annual financial results, revenue trends, liquidity updates and guidance changes, as reported in the company’s earnings releases and related Form 8‑K filings. These updates often discuss factors such as surgeon adoption of Treace’s expanded bunion technology portfolio, procedure volume dynamics and the impact of broader economic conditions on elective bunion surgery.
Treace also announces new technologies and product milestones, including developments in its Lapiplasty 3D Bunion Correction System, minimally invasive systems such as Nanoplasty and Percuplasty, the SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants and IntelliGuide patient specific planning and cut guide technology. News items may highlight first surgical cases with new platforms, transitions from limited market release to full market release and surgeon feedback on workflow and clinical use.
In addition, TMCI news includes updates on clinical studies like ALIGN3D and MTA3D, where interim data on radiographic correction, recurrence, pain and patient‑reported outcomes are presented at orthopedic conferences. Investors can also see announcements about debt financing arrangements, investor conferences, investor days and changes in board composition or governance roles.
For investors, clinicians and analysts tracking TMCI stock, this news feed offers a consolidated view of Treace’s financial disclosures, product pipeline developments and market‑facing activities related to bunion and midfoot deformity surgery.
Treace Medical Concepts (Nasdaq: TMCI) reported third quarter 2025 results on November 6, 2025 with revenue $50.2M (+11% YoY) and a net loss of $16.3M (or $(0.26) per share). Gross margin was 79.1%. Adjusted EBITDA loss improved 49% to $(2.6M). Total liquidity was $80.6M ($57.4M cash and marketable securities; $23.2M revolver availability).
The company released new 3D MIS and MTP fusion systems, presented positive clinical data, and expanded its patent portfolio to 122 granted and 194 pending patents. Treace cut full‑year 2025 revenue guidance to $211M–$213M (1%–2% growth) from $224M–$230M and now expects an Adjusted EBITDA loss of $6.5M–$7.5M for 2025, citing shifting surgeon preferences and softer elective procedure demand.
Treace Medical Concepts (NasdaqGS: TMCI) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Company management will host a conference call at 4:30 PM ET the same day to discuss results and answer questions.
Investors must register to receive dial-in numbers and a unique PIN to join the call. A live webcast and archived replay will be available on the company’s investor relations site at https://investors.treace.com/. Treace also posts investor‑important information regularly in the Investor Relations section of its website.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company focused on bunion treatment, announced significant product innovations and clinical study updates at the 2025 AOFAS Annual Meeting. The company unveiled several new technologies including Nanoplasty®, Percuplasty™, SpeedMTP®, and IntelliGuide™ PSI, expanding their bunion treatment portfolio.
The ALIGN3D™ clinical study data showed promising results with low radiographic recurrence rates of 7.7% at 48 months and 4.8% at 60 months. The MTA3D™ study demonstrated early weight-bearing capabilities averaging 7.9 days and significant improvements in both midfoot and 3D bunion deformity correction at 12 months.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in bunion treatment, reported Q2 2025 financial results with revenue of $47.4 million, up 7% year-over-year. The company reduced its net loss by 18% to $(17.4) million and improved adjusted EBITDA by 58% to $(3.6) million.
Key developments include the full market release of three new bunion technologies: Nanoplasty®, Percuplasty™, and SpeedMTP® systems. The company's Align3D™ technology received validation through four-year clinical data publication. Treace maintains its 2025 revenue guidance of $224-230 million, projecting 7-10% growth, and expects to achieve breakeven Adjusted EBITDA for full-year 2025.
The company's financial position includes $90.7 million in total liquidity, with cash usage decreasing by 55% in Q2 2025 compared to the prior year.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company focused on bunion and midfoot deformity treatments, will host an Investor Day on September 3, 2025, at 9:00 am ET in New York.
The event will feature presentations from management and experienced surgeons who will share their experiences with the company's expanded technology portfolio. Interested investors can register through investor relations by August 27, 2025. A live webcast and replay will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in bunion surgery solutions, has published four-year interim results from its ALIGN3D™ multicenter prospective study in the Journal of Foot & Ankle Surgery. The study, which followed 139 of 173 patients, demonstrated strong outcomes for the Lapiplasty® Procedure.
Key findings include an early return to protected weight bearing at 7.7 days, transition to athletic shoes at 6.5 weeks, and notably low recurrence rates of 0.8% using HVA>20° and 8.4% using HVA>15° at 48 months. Patient outcomes showed significant improvements, with an 81% reduction in pain and 89% improvement in walking/standing capabilities through the 48-month period.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in surgical treatments for bunions through its Lapiplasty® and Adductoplasty® Procedures, has scheduled its Q2 2025 earnings release for August 7, 2025 after market close.
The company will host a conference call at 4:30 PM ET to discuss the results. Investors can participate by registering to receive dial-in information. A webcast will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ: TMCI) reported its Q1 2025 financial results, showing revenue of $52.6 million, a 3% increase year-over-year. The company improved its net loss by 15% to $(15.9) million compared to $(18.7) million in Q1 2024. Adjusted EBITDA improved 53% to $(3.8) million from $(8.2) million in the same period.
The company expanded its bunion technology portfolio through limited releases of Nanoplasty™, Percuplasty™ 3D MIS Osteotomy Systems, and SpeedMTP™ MTP Fusion System. Treace maintained a strong gross margin of 79.7% and ended the quarter with total liquidity of $98.6 million. The company reaffirmed its full-year 2025 revenue guidance of $224-230 million, representing 7-10% growth, and expects to reach breakeven Adjusted EBITDA for 2025.
Treace Medical Concepts (TMCI), a medical technology company specializing in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 pm ET to discuss the results. Interested investors can participate by registering to receive dial-in numbers and a unique pin. A live and archived webcast will be available on the company's investor relations website at https://investors.treace.com/.